Active Ingredient History
The DPT vaccine or DTP vaccine is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis, and tetanus. The vaccine components include diphtheria and tetanus toxoids and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against in order to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain the pathogen itself, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest. However, booster doses are recommended every ten years to maintain immune protection against these pathogens. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Diphtheria-Tetanus-acellular Pertussis Vaccines (approved 2008)
Poliovirus Vaccines (approved 2008)
Bacterial Infections (Phase 3)
BCG Vaccine (Phase 4)
Dengue (Phase 2)
Dermatitis, Atopic (Phase 2)
Diphtheria (Phase 4)
Diphtheria Toxoid (Phase 4)
Drugs, Investigational (Phase 2)
Haemophilus influenzae (Phase 3)
Haemophilus influenzae type b (Phase 4)
Healthy Volunteers (Phase 3)
Hepatitis A (Phase 3)
Hepatitis A virus (Phase 4)
Hepatitis B (Phase 4)
HIV Infections (Phase 1/Phase 2)
Hypoxia (Phase 3)
Immunity (Phase 4)
Immunization (Phase 4)
Influenza, Human (Phase 2)
Malaria (Phase 3)
Malaria Vaccines (Phase 3)
Measles-Mumps-Rubella Vaccine (Phase 3)
Meninges (Phase 2)
Meningitis (Phase 4)
Meningitis, Bacterial (Phase 3)
Meningococcal Infections (Phase 3)
Meningococcal Vaccines (Phase 2)
Neisseria meningitidis (Phase 4)
Neoplasms, Glandular and Epithelial (Phase 3)
Papillomavirus Infections (Phase 3)
Pertussis Vaccine (Phase 4)
Pneumococcal Infections (Phase 3)
Pneumonia, Staphylococcal (Phase 3)
Poliomyelitis (Phase 4)
Poliovirus (Phase 4)
Poliovirus Vaccines (Phase 3)
Premature Birth (Phase 3)
Rotavirus Infections (Phase 3)
Streptococcal Infections (Phase 4)
Tetanus (Phase 4)
Vaccination (Phase 3)
Vaccines (Phase 4)
Virus Diseases (Phase 3)
Whooping Cough (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue